Mechanisms of allergyInhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy☆
Section snippets
Study subjects
Forty patients with a history of severe, seasonal, allergic rhinitis that was not controlled by antiallergic drugs and a positive skin-test reaction (weal > 5 mm) to Phleum pratense (Phl p; Aquagen, ALK-Abelló, Hørsholm, Denmark) were randomized to treatment with IT or placebo injections for 1 year. From a randomly selected subgroup of 10 patients (7 men, 3 women; mean age, 36 years; range, 18 to 58) on active treatment and 8 patients (2 men, 6 women; mean age, 38 years; range, 26 to 51) on
Allergen-IgE binding to B cells: effects of allergen concentration, incubation time, CD23 blockade, and serum dilution
Allergen-dependent binding of IgE to the surfaces of EBV-transformed B cells was detected as early as 10 minutes after incubation with atopic IgE-containing serum (Phl p-specific IgE, 789 SU/ml) that had been preincubated with serial dilutions of grass pollen allergen (Phl p; Fig 1, A). The binding of serum-IgE was clearly dependent on the dilution of IgE-containing serum (Fig 1, B) and concentration of the allergen. Optimal binding was detectable at a relatively low allergen concentration (3.0
Discussion
In this study, we show that binding of IgE antibodies to CD23 on the surfaces of B cells is dramatically enhanced by the presence of low allergen concentrations, consistent with formation of “polymeric” allergen-IgE complexes that bind CD23 with greater avidity than “monomeric” IgE. This allergen-IgE binding to B cells was associated with enhanced stimulation of allergen-specific T-cell clones, suggesting that binding of complexes translates functionally into enhanced antigen processing and
Acknowledgements
We thank Dr Terry G. Merrett (Allergy Diagnostics Laboratory, Abingdon, UK) for measuring IgG in the serum samples and Dr Peter Adler-Würtzen (ALK-Abelló, Hørsholm, Denmark) for helpful comments on the manuscript.
References (44)
- et al.
In vitro synthesis of IL-4 by human CD4+ T cells requires repeated antigenic stimulation
Cell Immunol
(1993) - et al.
Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial
J Allergy Clin Immunol
(2001) - et al.
Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study
Lancet
(2001) - et al.
A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses
J Allergy Clin Immunol
(1990) - et al.
Modified antigenic reactivity of anti-phospholipase A2 IgG antibodies in patients allergic to bee venom: conversion with immunotherapy and relation to subclass expression
J Allergy Clin Immunol
(1998) - et al.
Interleukin 4 is localized to and released by human mast cells
J Exp Med
(1992) - et al.
Secretion of IL-4 from human basophils: the relationship between IL-4 mRNA and protein in resting and stimulated basophils
J Immunol
(1994) - et al.
Evidence for compartmentalization of functional subsets of CD2+ T lymphocytes in atopic patients
J Immunol
(1990) - et al.
Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product
J Immunol
(1995) - et al.
Serum-IgE-facilitated allergen presentation in atopic disease
J Immunol
(1993)
The high affinity IgE receptor (FcϵRI) mediates IgE-dependent allergen presentation
J Immunol
Allergen presentation by epidermal Langerhans' cells from patients with atopic dermatitis is mediated by IgE
Immunology
Long-term clinical efficacy of grass-pollen immunotherapy
N Engl J Med
Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs
BMJ
Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium
Clin Exp Allergy
Decrease in reactivity of basophils by immunotherapy with housedust extract
Clin Allergy
Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy
Clin Exp Allergy
Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals
J Exp Med
Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures
J Immunol
Bee venom immunotherapy induces a shift in cytokine responses from a TH- 2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy
Clin Exp Allergy
Venom immunotherapy modulates interleukin-4 and interferon-γ messenger RNA expression of peripheral T lymphocytes
Immunology
Cited by (270)
Mechanisms and Predictive Biomarkers of Allergen Immunotherapy in the Clinic
2024, Journal of Allergy and Clinical Immunology: In PracticeThe role of IgG<inf>1</inf> and IgG<inf>4</inf> as dominant IgE-blocking antibodies shifts during allergen immunotherapy
2023, Journal of Allergy and Clinical ImmunologyTreating allergies via skin – Recent advances in cutaneous allergen immunotherapy
2022, Advanced Drug Delivery ReviewsAllergen immunotherapy for allergic airway diseases: Use lessons from the past to design a brighter future
2022, Pharmacology and TherapeuticsBlocking function of allergen-specific immunoglobulin G, F(ab')<inf>2</inf>, and Fab antibodies prepared from patients undergoing Dermatophagoides pteronyssinus immunotherapy
2022, Annals of Allergy, Asthma and ImmunologyDiverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma
2022, Journal of Allergy and Clinical Immunology
- ☆
Supported by the National Asthma Campaign and ALK-Abelló.